Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Regenxbio (RGNX) Accumulated Depreciation & Amortization (2016 - 2025)

Regenxbio (RGNX) has 11 years of Accumulated Depreciation & Amortization data on record, last reported at $83.5 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $83.5 million; the TTM value through Sep 2025 reached $83.5 million, changed N/A, while the annual FY2024 figure was $72.3 million, 26.37% up from the prior year.
  • Accumulated Depreciation & Amortization reached $83.5 million in Q3 2025 per RGNX's latest filing, up from $76.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $119.4 million in Q4 2021 and bottomed at $24.6 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $58.5 million, with a median of $53.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 50.98% in 2021, then crashed 65.33% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $119.4 million in 2021, then plummeted by 65.33% to $41.4 million in 2022, then skyrocketed by 38.22% to $57.2 million in 2023, then rose by 26.37% to $72.3 million in 2024, then increased by 15.56% to $83.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $83.5 million in Q3 2025, $76.2 million in Q1 2025, and $72.3 million in Q4 2024.